RU2018125034A - Ботулотоксин для лечения первичных расстройств настроения и аффекта при участии нейромедиатора - Google Patents
Ботулотоксин для лечения первичных расстройств настроения и аффекта при участии нейромедиатора Download PDFInfo
- Publication number
- RU2018125034A RU2018125034A RU2018125034A RU2018125034A RU2018125034A RU 2018125034 A RU2018125034 A RU 2018125034A RU 2018125034 A RU2018125034 A RU 2018125034A RU 2018125034 A RU2018125034 A RU 2018125034A RU 2018125034 A RU2018125034 A RU 2018125034A
- Authority
- RU
- Russia
- Prior art keywords
- disorder
- neurotransmitter
- brain
- violation
- pain
- Prior art date
Links
- 208000037920 primary disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 claims 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 239000002858 neurotransmitter agent Substances 0.000 claims 7
- 208000014644 Brain disease Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 108030001720 Bontoxilysin Proteins 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010043269 Tension headache Diseases 0.000 claims 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims 2
- 229940053031 botulinum toxin Drugs 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical group CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- 229960004373 acetylcholine Drugs 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 238000002610 neuroimaging Methods 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000005062 synaptic transmission Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Claims (23)
1. Способ лечения расстройства центральной нервной системы, определяемого как наличие нарушения по меньшей мере одного нейромедиатора мозга по меньшей мере в одной или нескольких областях головного мозга, предусматривающий способ:
a. инъекции ботулотоксина во внечерепную область головы или шеи;
b. таким образом, что внечерепная область головы и шеи находится в непосредственной близости с одной областью головного мозга с нарушенной активностью нейромедиатора, определенной при помощи ПЭТ-сканирования, функциональной магнитно-резонансной томографии или визуализации головного мозга;
c. при этом ботулотоксин блокирует нейропередачу, включающую по меньшей мере один нейромедиатор.
2. Способ по п. 1, где нейромедиатором является глутамат.
3. Способ по п. 1, где нейромедиатором является ацетилхолин.
4. Способ по п. 1, где нейромедиатором является ГАМК.
5. Способ по п. 1, где нейромедиатором является норадреналин.
6. Способ по п. 1, где нарушение головного мозга ассоциировано с большим депрессивным расстройством.
7. Способ по п. 1, где нарушение головного мозга ассоциировано с биполярным синдромом.
8. Способ по п. 1, где нарушение головного мозга ассоциировано с генерализованным тревожным расстройством и посттравматическим стрессовым расстройством.
9. Способ по п. 1, где расстройство связано с судорогами.
10. Способ по п. 9, где судороги включают очаговый двигательный и парциальный комплекс.
11. Способ по п. 1, где расстройство представляет собой нейродегенерацию, характеризующуюся как болезнь Альцгеймера, болезнь Паркинсона или хорея Гентингтона.
12. Способ по п. 1, где расстройство представляет собой острое нарушение мозгового кровообращения.
13. Способ по п. 1, где расстройство представляет собой гипертензию, опосредованную центральной нервной системой.
14. Способ по п. 13, где расстройство включают нецентральный компонент эссенциальной гипертезии.
15. Способ по п. 1, где расстройством является нарушение аппетита, которое представляет собой обсессивно-компульсивное расстройство.
16. Способ по п. 1, где расстройство представляет собой нарушение циркадианного ритма.
17. Способ по п. 1, где расстройство представляет собой нарушение сна.
18. Способ по п. 1, где расстройство представляет собой болевой синдром, характеризующийся как мигрень, головная боль напряжения, комбинированная головная боль напряжения и мигрень, невралгия тройничного нерва, миофасциальная боль, кластерная головная боль, послеоперационная травматическая боль.
19. Способ по п. 1, где расстройство представляет собой шизофрению.
20. Способ по п. 1, где расстройство представляет собой сезонное аффективное расстройство.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/966,759 US20160095908A1 (en) | 2005-06-14 | 2015-12-11 | Botulinum Toxin for Primary Disorders of Mood and Affect using Neurotransmitter CNS imaging Studies |
| US14/966,759 | 2015-12-11 | ||
| PCT/US2016/065898 WO2017100624A1 (en) | 2015-12-11 | 2016-12-09 | Botulinum toxin for primary disorders of mood and affect using neurotransmitter |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018125034A true RU2018125034A (ru) | 2020-01-13 |
| RU2018125034A3 RU2018125034A3 (ru) | 2020-04-15 |
Family
ID=59013649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018125034A RU2018125034A (ru) | 2015-12-11 | 2016-12-09 | Ботулотоксин для лечения первичных расстройств настроения и аффекта при участии нейромедиатора |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3386538A4 (ru) |
| JP (1) | JP2019504824A (ru) |
| KR (1) | KR20180093983A (ru) |
| CN (1) | CN109069609A (ru) |
| AU (1) | AU2016366428A1 (ru) |
| BR (1) | BR112018011663A2 (ru) |
| CA (1) | CA3007816A1 (ru) |
| CO (1) | CO2018007096A2 (ru) |
| IL (1) | IL259825A (ru) |
| MX (1) | MX2018007105A (ru) |
| RU (1) | RU2018125034A (ru) |
| SG (1) | SG11201804840SA (ru) |
| WO (1) | WO2017100624A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021137667A1 (ko) * | 2019-12-30 | 2021-07-08 | 주식회사 에이티지씨 | 보툴리눔 신경독소를 포함하는 파킨슨병 치료용 조성물 및 이를 이용한 파킨슨병 치료 방법 |
| GB202100566D0 (en) * | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| CN114384185A (zh) * | 2022-01-20 | 2022-04-22 | 北京航空航天大学 | 用于检测γ-氨基丁酸含量的试剂在制备诊断静脉流出障碍性疾病的试剂盒中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734810B2 (en) * | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
| US8609112B2 (en) * | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
| WO2005072433A2 (en) * | 2004-01-26 | 2005-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Toxin induced sympathectomy |
| US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
| US7655244B2 (en) * | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
| US8926991B2 (en) * | 2005-06-14 | 2015-01-06 | Botulinum Toxin Research Associates, Inc. | Botulinum toxin and the treatment of primary disorders of mood and affect |
| US20070218084A1 (en) * | 2005-12-30 | 2007-09-20 | Fondazione Pierfranco E Luisa Mariani- Onlus | Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy |
| CA2661220A1 (en) * | 2006-08-21 | 2008-02-28 | James R. Hauske | Multimediator transporter inhibitors for use in treatment of central nervous system disorders |
| JPWO2010013495A1 (ja) * | 2008-07-31 | 2012-01-05 | 一般財団法人化学及血清療法研究所 | 高度精製ボツリヌス毒素治療剤を有効成分として含有する薬学的組成物およびその利用 |
| US9393291B2 (en) * | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
| US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
-
2016
- 2016-12-09 CA CA3007816A patent/CA3007816A1/en not_active Abandoned
- 2016-12-09 WO PCT/US2016/065898 patent/WO2017100624A1/en not_active Ceased
- 2016-12-09 SG SG11201804840SA patent/SG11201804840SA/en unknown
- 2016-12-09 CN CN201680079413.0A patent/CN109069609A/zh active Pending
- 2016-12-09 RU RU2018125034A patent/RU2018125034A/ru not_active Application Discontinuation
- 2016-12-09 KR KR1020187019212A patent/KR20180093983A/ko not_active Withdrawn
- 2016-12-09 MX MX2018007105A patent/MX2018007105A/es unknown
- 2016-12-09 AU AU2016366428A patent/AU2016366428A1/en not_active Abandoned
- 2016-12-09 JP JP2018529573A patent/JP2019504824A/ja active Pending
- 2016-12-09 BR BR112018011663A patent/BR112018011663A2/pt not_active IP Right Cessation
- 2016-12-09 EP EP16873950.6A patent/EP3386538A4/en not_active Withdrawn
-
2018
- 2018-06-05 IL IL259825A patent/IL259825A/en unknown
- 2018-07-06 CO CONC2018/0007096A patent/CO2018007096A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180093983A (ko) | 2018-08-22 |
| CN109069609A (zh) | 2018-12-21 |
| EP3386538A1 (en) | 2018-10-17 |
| EP3386538A4 (en) | 2019-07-17 |
| AU2016366428A1 (en) | 2018-06-28 |
| BR112018011663A2 (pt) | 2018-12-04 |
| CO2018007096A2 (es) | 2018-11-22 |
| MX2018007105A (es) | 2018-09-07 |
| IL259825A (en) | 2018-07-31 |
| WO2017100624A1 (en) | 2017-06-15 |
| CA3007816A1 (en) | 2017-06-15 |
| JP2019504824A (ja) | 2019-02-21 |
| SG11201804840SA (en) | 2018-07-30 |
| RU2018125034A3 (ru) | 2020-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Faggiani et al. | Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: From history to the interaction with the monoaminergic systems | |
| RU2018125034A (ru) | Ботулотоксин для лечения первичных расстройств настроения и аффекта при участии нейромедиатора | |
| Slattery et al. | Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review | |
| Kerestes et al. | Functional brain imaging studies of youth depression: a systematic review | |
| Laxpati et al. | Deep brain stimulation for the treatment of epilepsy: circuits, targets, and trials | |
| Titov et al. | Disorder-specific versus transdiagnostic and clinician-guided versus self-guided treatment for major depressive disorder and comorbid anxiety disorders: a randomized controlled trial | |
| Firouzabadi et al. | Effectiveness of detached mindfulness techniques in treating a case of obsessive compulsive disorder. | |
| Bunse et al. | Motor cortical excitability assessed by transcranial magnetic stimulation in psychiatric disorders: a systematic review | |
| Blázquez et al. | Cognitive and emotional profiles of aged Alzheimer's disease (3× TgAD) mice: effects of environmental enrichment and sexual dimorphism | |
| ECSP19048477A (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| EA201300975A1 (ru) | Новые композиции для лечения неврологических заболеваний | |
| CO2021002087A2 (es) | Método para tratar la epilepsia | |
| EA201792437A1 (ru) | Способы и композиции для лечения нарушений, ассоциированных со старением | |
| CO2019002839A2 (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| EA201691602A1 (ru) | Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств | |
| Parain et al. | Large-field repetitive transcranial magnetic stimulation with circular coil in the treatment of functional neurological symptoms | |
| IL313097A (en) | Methods of treating cns disorders | |
| EP3943107A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF BRAIN AND NERVOUS SYSTEM DISEASES | |
| MX385967B (es) | Método para la maduración rápida de alcoholes destilados usando procesos de luz y calor. | |
| MX2010010233A (es) | Compuestos novedosos utiles en el tratamiento de afecciones y trastornos del sistema nervioso central. | |
| JP2014500885A5 (ru) | ||
| WO2014111525A3 (en) | Combination therapies for treating nervous system diseases | |
| EP4446417A4 (en) | A variant of Corynebacterium glutamicum with an improved capacity to produce L-lysine and a process for producing L-lysine using it | |
| RU2016152150A (ru) | Ботулинический токсин для применения в лечении паратонии | |
| SUN et al. | Clinical effect and electroencephalographic oscillation changes of the repetitive transcranial magnetic stimulation and eszopiclone treatment of chronic insomnia disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20211203 |